Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Oct 1;27(19):4540-4543.
doi: 10.1016/j.bmcl.2017.08.056. Epub 2017 Aug 30.

Synthesis and anti-enterovirus activity of new analogues of MDL-860

Georgi M Dobrikov  1 , Ivaylo Slavchev  2 , Ivanka Nikolova  3 , Adelina Stoyanova  3 , Nadya Nikolova  3 , Lucia Mukova  3 , Rosica Nikolova  4 , Boris Shivachev  4 , Angel S Galabov  5
Affiliations

Synthesis and anti-enterovirus activity of new analogues of MDL-860

Georgi M Dobrikov et al. Bioorg Med Chem Lett. .

Abstract

A series of twelve novel compounds, analogues of antiviral agent MDL-860 were synthesized and their antiviral activity was evaluated in vitro against enteroviruses poliovirus 1 (PV1), Coxsackieviruses B1 (CVB1) and Coxsackieviruses B3 (CVB3). Compounds 14, 24 and 25 manifested strong antiviral effects against CVB1 and PV1 (SI values of 405 and 118 for CVB1 and PV1 respectively). In contrast to the wide anti-enteroviral activity of MDL-860, these three compounds were inactive against CVB3. Compounds 14, 24 and 25 along with MDL-860 were tested in vivo in mice infected with CVB1. Marked protective effects of compounds 14 and 24 were established, PI values of 50% and 33.3%, respectively. In addition, almost all of the tested compounds manifested very low toxicity.

Keywords: Coxsackieviruses; Diarylethers; Enterovirus; MDL-860; Polio.

PubMed Disclaimer

Publication types